Дифференцированный подход к ведению больных хроническим гломерулонефритом с учетом генетической предрасположенности
Диссертация
Результаты современных исследований демонстрируют повышение риска 7 хронизации гломерулонефрита при высокой концентрации гомоцистеина в крови. В основе этого процесса лежат несколько механизмов: непосредственное токсическое воздействие гомоцистеина на эндотелий, активация гиперплазии гладкомышечного слоя сосудистой стенки. Гомоцистеин стимулирует агрегацию тромбоцитов, нарушает функцию тканевого… Читать ещё >
Список литературы
- Е.И.Баранова, О. О. Большакова. Кафедра факультетской терапии СПб ГМУ им. акад. И. П. Павлова. Артериальная гипертензия. том 10№ 1 /2004
- Гомазков O.A. Эндотелии в кардиологии: молекулярные, физиологические и патологические аспекты // Кардиология. 2001. — № 2. — С.50−58.
- Дроздова Г. А. Клеточные механизмы артериальной гипертензии // Патологическая физиология. 2000. — № 3. — С.26−31.
- В.А. Добронравов, Р. В. Голубев. Гипергомоцистеинемия фактор риска сердечно-сосудистых поражений у диализных больных и в общей популяции Санкт-Петербург, Россия Нефрология, 2004, том 8, приложение 2, стр. 44−49.
- Елисеева Ю.Е. 2001г. Вопросы медицинской химии, № 1 106−129.
- И. Гузов 2006 Новая генетика (Геномика в профилактике осложнений беременности)
- Коношкова PJL Ишемические изменения миокарда у больных с хронической почечной недостаточностью, получающих терапию гемодиализом. Нефрология 2000- 3: 18−26
- Малкоч A.B., Майданник В. Г. Нефрология и диализ, Курбанова Э.Г. Физиологическая роль оксида азота в организме (часть 1) //. 2000. — Т. 2. — № 1−2. -С. 69−75.
- О.Минушкина 2002 -02−18 Гены эндотелиальных факторов и артериальная гипертония
- Паунова С.С., Кучеренко А. Г., Марков Х. М. и др. Патогенетическая роль тромбоцитарного оксида азота в формировании нефропатий у детей // Нефрология и диализ. 2000. — Т. 2. — № 1−2. — С. 48−51.
- Ребров А. П., Зелепукина Н. Ю. Дисфункция эндотелия у больных хроническим гломерулонефритом в различных стадиях почечной недостаточности РДО «ЖурналНефрология и диализ» «Т. 3, 2001 г., № 4
- И.Е. Тареева. Новый данные о механизмах прогрессирования гломерулонефрита. Materia Medica, 1995, № 2, с. 5−19.
- И.Е. Тареева,. Нефрология (руководство для врачей) в 2 томах, под редакцией И. Е. Тареевой, М. Медицина, 1995.
- Тареева И.Е. ШиловЕ.М. Современные представления о гломерулонефрите. РМЖ, том 5 № 23 .1997 с 1516−20.
- И.Е. Тареева. Новый данные о механизмах прогрессирования гломерулонефрита. Materia Medica, 1995, № 2, с. 5−19.
- И.Е.Тареева. Гломерулонефриты: клиника, лечение. Русский Медицинский. Журнал. Т.8 № 3 .2000 год.
- Чиж А. С. Почки: болезни, профилактика и лечение. Справочное пособие. Изд-во: Белорусская навука Год 2004 стр. 240.
- Чиж А. С. Современные представления об этиологии и патогенезе диффузного гломерулонефрита // Здравоохр. Белоруссии. 1972. № 4. С. 2−6.
- Чиж А. С., Корзун А. С. Профилактика, противорецидивное лечение и диспансеризация больных с заболеваниями почек: Метод, рекомендации. Мн., 1980.
- Шарнова Ж.П., Цыгин А. Н., Пинелис В. Г., Тихомиров Е. Е. Влияние I/D полиморфизма гена ангиотензин превращающего фермента на прогрессирование заболеваний почек у детей. Сборник тезисов ноябрь 2005 г. VI съезд научного общества нефрологов России. Стр. 53.
- Шахмалова М.Ш., Шестакова М. В., Чугунова Л. А., Дедов И. И. Вазоактивные факторы эндотелия сосудов у больных инсулин-независимым сахарным диабетом с поражением почек // Тер. архив. 199.6 — № 6. — С. 43−45.
- Шевченко О.П., Олефриенко Г. А. Гипергомоцистеинемия и ее клиническое значение. Лаборатория. 2002- 1: 3−7.
- Atcins R.N. Гломерулонефриты. Австралия Журнал «Нефрология и диализ» том 2 .2000№ 4.Стр.225−229.
- Anggard Е. Nitric oxide: mediator, murderer and medicine. Lancet 1994- 343: 11 991 206.
- Anderson, PW, Zhang XY, Tian J, Correale JD, Xi XP, Yang D, Graf K, Law RE, and Hsueh WA. Insulin and angiotensin II are additive in stimulating TGF-beta 1 and matrix mRNAs in mesangial cells. Kidney Int 50: 745−753, 1996
- Amoroso A., Danek G., Vatta S. et al. Polymorphism in angiotensin-converting enzyme gene and severity of renal disease in Henoch-Schoenlein patients // Nephrol. Dial. Transplant. 1998. — Vol. 13. P. 3184−3188.
- Asano T., Tatsuma N., Yoshida J. et al. Association of angiotensin-converting enzyme gene polymorphism and renal pathology in Japanese children with IgA nephropathy // Clin. Nephrol. 1999. — Vol. 51. — P. 335−340.JIeHa
- Akai Y., Sato H., Iwano M. et al. Association of an insertion polymorphism of angiotensin-converting enzyme gene with the activity of lupus nephritis // Clin. Nephrol. 1999.-Vol. 51.-P. 141−6.
- Beige J., Scherer S., Weber A. et al. Angiotensin-converting enzyme genotype and renal allograft survival // J. Am. Soc. Nephrol. 1997. — Vol. 8. — P. 1319−1323.
- Baboolal K., Ravine D., Daniels J. et al. Association of the angiotensin I converting enzyme gene deletion polymorphism with early onset of ESRF in PKD1 adult polycystic kidney disease // Kidney Int. 1997. — Vol. 52. — P. 607−613.
- Bostom AG, Lathrop L. Hyperhomocysteinemia in end-stage renal disease: prevalence, etiology, and potential relationship to arteriosclerotic outcomes. Kidney Int 1997- 52(1): 10−20
- Buccianti G, Raselli S, Baragetti I et al. 5-methyltetrahydrofolate restores endothelial function in uraemic patients on convective haemodialysis. Nephrol Dial Transplant 2002- 17(5): 857−864
- Booth G, Wang E. Preventive health care, 2000 update: screening and management of hyperhomocysteinemia for the prevention of coronary artery disease events. CMAJ 2000- 163(1): 21−9.
- Blacher J, Benetos A, Kirzin J et al. Relation of plasma homocysteine to cardiovascular mortality in a French population. Am J Cardiol 2002- 90 (6): 591−5.
- Bergstrom J, Furst P. Uraemic toxins. In: Drukker W, Parsons FM, Maher JF (eds.) Replacement of renal function by dialysis. 2nd ed. Boston: Martinus Nijhoff publishers- 1984:354−391
- Barnes, JL, Mitchell RJ, and Torres ES. Expression of plasminogen activator-inhibitor-1 (PAI-1) during cellular remodeling in proliferative glomerulonephritis in the rat. J Histochem Cytochem 43: 895−905, 1995
- Bergstein, JM, Riley M, and Bang NU. Role of plasminogen-activator inhibitor type 1 in the pathogenesis and outcome of the hemolytic uremic syndrome. N Engl J Med 327: 755−759, 1992
- Blasi, F. uPA, uPAR, PAI-1: key intersection of proteolytic, adhesive, and chemotactic highways? Immunol Today 18: 415−417, 1997
- Besbas, N, Erbay A, Saatci U, Ozdemir S, Bakkaloglu A, Ozen S, and Topaloglu R. Thrombomodulin, tissue plasminogen activator and plasminogen activator inhibitor-1 in Henoch-Schonlein purpura. Clin Exp Rheumatol 16: 95−98, 1998
- Brown, NJ, Nakamura S, Ma L, Nakamura I, Donnert E, Freeman M, Vaughan DE, and Fogo AB. Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo. Kidney Int 58: 1219−1227, 2000
- Border, WA, and Noble NA. Transforming growth factor P in tissue fibrosis. N Engl J Med 331: 1286−1292, 1994
- Coppola A, Davi G, De Stefano V et al. Homocysteine, coagulation, platelet function, and thrombosis. Semin Thromb Hemost 2000- 26: 243−54.
- Border W.A., Noble N.A. Interactions of transforming growth factor-3 and angiotensin II in renal fibrosis. Hypertension 1998- 31: 181−188.
- Chauveau P, Chadefaux B, Coude M et al. Hyperhomocysteinemia, a risk factor for atherosclerosis in chronic uremic patients. Kidney Int 1993- 43 Suppl 41.: 72−77
- Chandler, W, Jelacic S, Boster D, Ciol M, Williams G, Watkins S, Igarashi T, and Tarr P. Prothrombotic coagulation abnormalities during Escherichia coli 0157: H.7 infections. N Engl J Med 346: 23−32, 2002
- Carmeliet, P, Kieckens L, Schoonjans L, Ream B, Van Nuffelen A, Prendergast
- Cambien F. The angiotensin-converting enzyme (ACE) genetic polymorphism: Its relationship with plasma ACE level and myocardial infarction // Clin. Genet. 1994. -V. 46.-P. 94−101.
- Cambien F., Poirier O., Lecerf L. et al. Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction // Nature. 1992. — Vol. 359. — P.641−644.
- G, Cole M, Bronson R, Collen D, and Mulligan RC. Plasminogen activator inhibitor-1 gene-deficient mice. 1. Generation by homologous recombination and characterization. J Clin Invest 92: 2746−2755, 1993
- Diet F., Pratt R.E., Berry G.J., Momose N. et al. (1996) Circulation, 94, 2756−2767
- Dorer F.E., Kahn J.R., Lentz K.E. et al. (1974) Circ. Res., 34, 824−827.
- Danser A.H., Schalekamp M.A., Bax W.A. et al. (1995) Circulation, 92, 1387−1388.
- Duymelinck, C, Dauwe SEH, De Greef KEJ, Ysebaert DK, Verpooten GA, and De Broe ME. TIMP1 gene expression and PAI-1 antigen after unilateral ureteral obstruction in the adult male rat. Kidney Int 58: 1186−1201, 2000
- Ducloux D, Ruedin C, Gibey R et al. Prevalence, determinants, and clinical significance of hyperhomocyst (e)inaemia in renal-transplant recipients. Nephrol Dial Transplant 1998- 13(11): 2890−2893
- Duymelinck, C, Dauwe SE, Nouwen EJ, DeBroe ME, and Verpooten GA. Cholesterol feeding accentuates the cyclosporine-induced elevation of renal plasminogen activator inhibitor type I. Kidney Int 51: 1818−1830, 1997
- Eddy, AA. Interstitial inflammation, and fibrosis in rats with diet-induced hypercholesterolemia. Kidney Int 50: 1139−1149, 1996
- Egido J. Vasoactive hormones and renal sclerosis. Kidney Int 1996- 49: 578−597.
- Elisa A., Haider M.Z., Srivastva B.S. Angiotensin converting enzyme gene insertion/deletion polymorphism in idiopathic nephrotic syndrome in Kuwqaiti Arab children // Scan. J. Urol. Nephrol. 2001. — Vol. 35. — P. 239−242.
- Erdos E.G. (1979) Handbook of Experimental Pharmacology, 25, (Suppl.5.), 438 487.
- Egido J. Vasoactive hormones and renal sclerosis. Kidney Int 1996- 49: Genser D. Homocysteine, vitamins, and restenosis after percutaneous coronary intervention. Cardiovasc Rev Rep 2003- 24 (5): 253−8.
- El Nahas A.M. Progression of chronic renal failure. In: Johnson R.J., Feehally J., eds. Comprenhensive Clinical Nephrology. New-York: Mosby Harcourt 2000: 67−1-67−10.
- Fay, WP, Shapiro AD, Shih JL, Schleef RR, and Ginsburg D. Brief report: complete deficiency of plasminogen-activator inhibitor type 1 due to a frame-shift mutation. N Engl J Med 327: 1729−1733, 1992
- Fogo, AB. The role of angiotensin II, and plasminogen activator inhibitor-1 in progressive glomerulosclerosis. Am J Kidney Dis 35: 179−188, 2000
- Fogo, AB. Progression, and potential regression of glomerulosclerosis. Kidney Int 59: 804−819, 2001
- Frishberg Y., Becker-Cohen R., Halle D. et al. Genetic polymorphisms of the renin-angiotensin system and the outcome of focal segmental glomerulosclerosis in children // Kidney Int. 1998. — Vol. 54. — P. 1843−1849
- Fu W, Dudman N, Perry M, Wang X. Homocysteinemia attenuates hemodynamic responses to nitric oxide in vivo. Atherosclerosis 2002- 161 (1): 169−76.
- Fowler B. The folate cycle and disease in humans. Kidney Int 2001- 59 Suppl 78.: 221−229
- Fodinger M, Mannhalter C, Wolfl G et al. Mutation (677 C to T) in the methyltetrahydrofolate reductase gene aggravates hyperhomocysteinemia in hemodialysis patients. Kidney Int 1997- 52 (2): 517−523
- Guttormsen AB, Ueland PM, Svarstad E, Refsum H. Kinetic basis of hyperhomocysteinemia in patients with chronic renal failure. Kidney Int 1997- 52 (2): 495−502
- Grandaliano, G, Gesualdo L, Ranieri E, Monno R, and Schena FP. Tissue factor, plasminogen activator inhibitor-1, and thrombin receptor expression in human crescentic glomerulonephritis. Am J Kidney Dis 35: 726−738, 2000
- Gupta S., Clarkson M.R., Duggan J. et al. Connective tissue growth factor: potential role in glomerulosclerosis and tubulointerstitial fibrosis. Kidney Int 2000- 58: 1389−1399.
- Harker L, Ross R, Slichter S, Scott C. Homocysteinemia: vascular injury and arterial thrombosis. N Engl J Med 1974- 291: 53713. 578−597.
- Hansrani M, Gillespie J, Stansby G. Homocysteine in myointimal hyperplasia. Eur J Vase Endovasc Surg 2002- 23: 3−10.
- Hamano, K, Iwano M, Akai Y, Sato H, Kubo A, Nishitani Y, Uyama H, Yoshida Y, Miyazaki M, Shiiki H, Kohno S, and Dohi K. Expression of glomerular plasminogen activator inhibitor type 1 in glomerulonephritis. Am J Kidney Dis 39: 695−705, 2002
- Harden PN, Geddes C, Rowe PA, Mcllroy JH, Boulton-Jones M, Rodger RSC, Junor BJR, Briggs JD, Connel JMC, Jardine AG. Polymorphism in angiotensin-convertingenzyme gene and progression of IgA nephropathy // Lancet. 1995. — Vol. 345. — P. 1540−1542.
- Hagen W, Fodinger M, Heinz G et al. Effect of MTHFR genotypes and hyperhomocysteinemia on patient and graft survival in kidney transplant recipients. Kidney Int 2001- 59 Suppl 78.: 253−257
- Hamano, K, Iwano M, Akai Y, Sato H, Kubo A, Nishitani Y, Uyama H, Yoshida Y, Miyazaki M, Shiiki H, Kohno S, and Dohi K. Expression of glomerular plasminogen activator inhibitor type 1 in glomerulonephritis. Am J Kidney Dis 39: 695−705, 2002.
- Haraguchi, M, Border WA, Huang Y, and Noble NA. t-PA promotes glomerular plasmin generation and matrix degradation in experimental glomerulonephritis. Kidney Int 59: 2146−2155, 2001
- Hamano, K, Iwano M, Akai Y, Sato H, Kubo A, Nishitani Y, Uyama H, Yoshida Y, Miyazaki M, Shiiki H, Kohno S, and Dohi K. Expression of glomerular plasminogen activator inhibitor type 1 in glomerulonephritis. Am J Kidney Dis 39: 695−705, 2002
- Haraguchi, M, Border WA, Huang Y, and Noble NA. t-PA promotes glomerular plasmin generation and matrix degradation in experimental glomerulonephritis. Kidney Int 59: 2146−2155, 2001
- Hubert C., Houot A.-M., Corvol P., Soubrier F. (1991) J. Biol. Chem., 266, 1 537 715 383
- Hayakawa H., Raij L. The link among nitric oxide synthase activity, endothelial function, and aortic and ventricular hypertrophy in hypertension // Hypertension. 1997. -Vol. 29.-P. 235−241.
- Hunley T.E., Julian B.A., Phillips J.A. et al. Angiotensin converting enzyme gene polymorphism: potential silencer motif and impact on progression in IgA nephropathy // Kidney Int. 1996. — Vol. 49. — P. 571−577.
- Hooper N.M. (1991) Int. J. Biochem., 23, 641−647.
- Jacques PF, Bostom AG, Williams RR et al. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation 1996- 93 (1): 7−9
- Kanani P, Sinkey C, Browning R et al. Role of oxidant stress in endothelial dysfunction produced by experimental hyperhomocysteinemia in humans. Circulation 1999- 100: 1161−8.
- Konoshita T., Miyagi K., Onoe T. et al. Effect of ACE gene polymorphism on age at renal death in polycystic kidney disease in Japan // Am. J. Kidney Dis. 2001. — Vol. 37. -P. 113−118
- Kahleov R, Palyzova D, Zvar3 K et al. Essential hypertension in adolescents: association with insulin resistance and with metabolism of homocysteine and vitamins. Am J Hypetens 2002- 15 (10): 857−64.
- Kark J, Seihub J, Adler B et al. Nonfasting plasma total homocysteine level and mortality in middle-aged and elderly men and women in Jerusalem. Ann Int Med 1999- 131 (5): 321−30.
- Khan IN, Protesi A, Yiannakis E et al. Homocysteinaemia in patients receiving renal replacement therapy (RRT): relationship with dietary nutrient intake and mode of RRT. Nephrol Dial Transplant 1997- 12(11): 2470−2471
- Kunz K, Petitjean P, Lisri M et al. Cardiovascular morbidity and endothelial dysfunction in chronic HD patients: is homocysteine the missing link? Nephrol Dial Transplant 1999- 14(8): 1934−1942
- Keeton, M, Ahn C, Eguchi Y, Burlingame R, and Loskutoff DJ. Expression of type 1 plasminogen activator inhibitor in renal tissue in murine lupus nephritis. Kidney Int 47: 148−157, 1995
- Keeton, M, Eguchi Y, Sawdey M, Ahn C, and Loskutoff DJ. Cellular localization of type 1 plasminogen activator inhibitor messenger RNA and protein in murine renal tissue. Am J Pathol 142: 59−70, 1993
- Kerins, DM, Hao Q, and Vaughan DE. Angiotensin induction of PAI-1 expression in endothelial cells is mediated by the hexapeptide angiotensin IV. J Clin Invest 96: 2515−2520, 1995
- Lapinski R., Perico N., Remuzzi A. et al. Angiotensin II modulates glomerular capillary permselectivity in rat isolated perfused kidney. J Am Soc Nephrol 1996- 7: 653 660.
- Libetta C, Villa G, Pirrelli S et al. Homocysteine plasma levels correlate with intimai carotid artery thickness in hemodialysis patients. Nephrol Dial Transplant 2001- 16 (12): 2444−2445
- Lee D.Y., Kim W., Kang S.K. et al. Angiotensin-Converting enzyme gene polymorphism in patients with minimal-change nephrotic syndrome and focal segmental glomerulosclerosis // Nephron. 1997. — Vol. 77. — P. 471−473.
- Liangos O, Kreutz R, Beige J et al. Methylenetetrahydrofolate-reductase gene C677T variant and kidney-transplant survival. Nephrol Dial Transplant 1998- 13 (9): 2351−2354
- Lim S, Kim M, Park K et al. Correlation of plasma homocysteine and mytochondrial DNA content in peripheral blood of healthy women. Atherosclerosis 2001- 158 (2): 399 405.
- Loskutoff, DJ, Curriden SA, Hu G, and Deng G. Regulation of cell adhesion by PAI-1. APMIS 107: 54−61, 1999
- Largo R., Gomez-Garre D., Soto K. et al. Angiotensin-Converting enzyme is upregulated in the proximal tubules of rats with intense proteinuria. Hypertension 1999- 33: 732−739.
- Loscalo J. The oxidant stress ofhyperhomocyst (e)inemia. J Clin Invest 1996- 98 (1): 5−7.
- Loehrer FMT, Angst CP, Brunner FP et al. Evidence for disturbed S-adenosylmethionine: S-adenosylhomocysteine ratio in patients with ESRF: a cause for disturbed methylation reactions? Nephrol Dial Transplant 1998- 13 (3): 656−661
- Liangos O, Kreutz R, Beige J et al. Methylenetetrahydrofolate-reductase gene C677T variant and kidney-transplant survival. Nephrol Dial Transplant 1998- 13 (9): 2351−2354
- Ludwig E., Corneli P. S., Anderson J.L. et al. Angiotensin-Converting enzyme gene polymorphism is associated with myocardial infarction but not with development of coronary stenosis // Circulation. 1995. — Vol. 91. — P. 2120−2124.
- Marre M., Bernadet P., Gallois Y. et al. Relationships between angiotensin I converting enzyme gene polymorphism, plasma levels, and diabetic retinal and renal complication // Diabetes. 1994. — Vol. 43. — P. 384−388.
- Mayer E, Jacobsen D, Robinson K. Homocysteine and coronary atherosclerosis. J Am Coll Cardiol 1996- 27: 517−27.
- Martin, AA, Woolven BL, Harris SJ, Keeley SR, Adams LD, Jureidini KF, and Henning PH. Plasminogen activator inhibitor type-1 and interleukin-6 in haemolytic uraemic syndrome. J Paediatr Child Health 36: 327−331, 2000
- Mezzano S., Ruiz-Ortega M., Egido J. Angiotensin II and Renal Fibrosis. Hypertension. 2001- 38: 635−640.
- Mezzano S., Droguett M.A., Burgos M.E. et al. Overexpression of chemokines, fibrogenic cytokines, and myofibroblasts in human membranous nephropathy. Kidney Int 2000- 57: 147−158.
- Ma, LJ, Nakamura S, Whitsitt JS, Marcantoni C, Davidson JM, and Fogo AB. Regression of sclerosis in aging by an angiotensin inhibition-induced decrease in PAI-1. Kidney Int 58: 2425−2436, 2000
- Mayer E, Jacobsen D, Robinson K. Homocysteine and coronary atherosclerosis. J Am Coll Cardiol 1996- 27: 517−27.
- Maruyama K., Yoshida M., Nisho H. et al. Polymorphisms of renin-angiotensin system genes in childhood IgA nephropathy // Pediatr. Nephrol. 2001. — Vol. 16. — P. 350−355.
- Moreno H, Kuffaty J, Croce N et al. Homocysteinemia and its relation with risk factor for arterial hypertension. Am J Hypertens 2002- 15 (4, suppl. 1): P. A218.
- Moland Y., Gal E., Magal N. et al. Renal outcome and vascular morbidity in systemic lupus erythematosus (SLE): lack of association with the angiotensin-converting enzyme gene polymorphism // Semin. Arthritis. Rheum. 2000. — Vol. 30. — P. 132−7.
- Moncada S., Grygiewski R.I., Bunting S. An enzime isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 1976- 263: p 663−665
- McCully KS. Homocysteine, folate, vitamin B6 and cardiovascular disease. JAMA 1998- 279 (5): 392−393
- Mezzano D, Pais E, Aranda E et al. Inflammation, not hyperhomocysteinemia, is related to oxidative stress and hemostatic and endothelial dysfunction in uremia. Kidney Int 2001- 60 (5): 1844−1851
- Nakamura, S, Nakamura I, Ma L, Vaughan DE, and Fogo AB. Plasminogen activator inhibitor-1 expression is regulated by the angiotensin type 1 receptor in vivo. Kidney Int 58: 251−259, 2000
- Nevard, CH, Jurd KM, Lane DA, Philippou H, Haycock GB, and Hunt BJ. Activation of coagulation and fibrinolysis in childhood diarrhoea-associated haemolytic uraemic syndrome. Thromb Haemost 78: 1450−1455, 1997
- Nakamura, S, Nakamura I, Ma L, Vaughan DE, and Fogo AB. Plasminogen activator inhibitor-1 expression is regulated by the angiotensin type 1 receptor in vivo. Kidney Int 58: 251−259, 2000
- Nakamura S., Nakamura I., Ma L. et al. Plasminogen activator inhibitor-1 expression is regulated by the angiotensin type 1 receptor in vivo. Kidney Int 2000- 58: 251−259.
- Oda, T, Jung YO, Kim H, Cai X, Lopez-Guisa J, Ikeda Y, and Eddy AA. PAI-1 deficiency attenuates the fibrogenic response to ureteral obstruction. Kidney Int 30: 587 596, 2001
- Oikawa, T, Freeman M, Lo W, Vaughan DE, and Fogo A. Modulation of plasminogen activator inhibitor-1 in vivo: a new mechanism for the anti-fibrotic effect of renin-angiotensin inhibition. Kidney Int 51: 164−172, 1997
- Ong-Ajyooth S., Ong-Ajyooth L., Limmongkon A. et al. The renin-angiotensin system gene polymorphisms and clinicopathological correlations in IgA nephropathy // J. Med. Assoc. Thai. 1999. — Vol. 82. — P. 681−689.
- Pfeilscbifter J. et al. Nitric oxide an inflammatory mediator of glomerular mesangial cells. Nephron 1993- 64- 4: 518−25.
- Pei Y., Scholey J., Thai K. et al. Association of angiotensinogen gene T235 variant with progression of immunoglobin A nephropathy in Caucasian patients // J. Clin. Invest. 1997. — Vol. 100. — P. 814−820.
- Prkacin I., Novak B., Sertie J., Mrzljak A. Angiotensin-Converting enzyme gene polymorphism in patients with systemic lupus // Acta Med. Croatica. 2001. — Vol. 55. -P 73−76.
- Perna AF, Ingrosso D, De Santo NG et al. Mechanism of erythrocyte accumulation of methylation inhibitor S-adenosylhomocysteine in uremia. Kidney Int 1995- 47 (1): 247−253
- Perna AF, Ingrosso D, Castaldo P et al. Homocysteine and transmethylations in uremia. Kidney Int 2001- 59 Suppl 78.: 230−233
- Peters, H, Border WA, and Noble NA. Angiotensin II blockade and low-protein diet produce additive therapeutic effects in experimental glomerulonephritis. Kidney Int 57: 1493−1501,2000
- Ruiz-Ortega M., Lorenzo O., Suzuki Y. et al. Proinflammatory actions of angiotensin II. Curr Opin Nephrol Hypertens 2001- 10: 321−329.
- Rosenthal AF, Ginsberg MJ, Crawford JF. Homocysteine and heart disease in dialysis patients. Dial Transpl 1998- 27 (10): 627−630
- Radtke, KP, Fern’andez JA, Greengard JS, Tang WW, Wilson CB, Loskutoff DJ, Scharrer I, and Griffin JH. Protein C inhibitor is expressed in tubular cells of human kidney. J Clin Invest 94: 2117−2124, 1994
- Rerolle, JP, Hertig A, Nguyen G, Sraer JD, and Rondeau E. Plasminogen activator inhibitor type 1 is a potential target in renal fibrogenesis. Kidney Int 58: 1841−1850, 2000
- Radomsky M., Palmer R., Moncada S. An L-arginin/nitric oxide pathway present in human platelet regulation aggregation. Proc. Natl. Acad. Sei. USA. 1990- 87- 5: 193−97.
- Ruiz-Ortega M., Egido J. Angiotensin II modulates cell growth-related events and synthesis of matrix proteins in renal interstitial fibroblasts. Kidney Int 1997- 52: 14 971 510.
- Remuzzi G., Ruggenenti P., Begnini A. Understanding the nature of renal disease progression. Kidney Int 1997- 51: 2−15.
- Rubin B., Antonaccio M.J., Horovitz Z.P. (1978) Progr. in Cardiovasc. Dis., 21, 183−194.
- Ramchandran R., Kasturi S., Douglas J.G., Sen I. (1996) Am. J. Physiol. Heart and Circulatory Physiology, 40, 744-H751
- Rigat B., Hubert C., Alhenc-Gelas F., Cambien F. et al. (1990) J. Clin. Invest., 86, 1343−1346.
- Rigat B., Hubert C., Corvol P., Soubrier F. (1992) Nucleic Acids Res., 20, 1433.
- Sawdey, MS, and Loskutoff DJ. Regulation of murine type 1 plasminogen activator inhibitor gene expression in vivo. J Clin Invest 88: 1346−1353, 1991.
- Schena F., D’Altri C., Cerullo G. et al. ACE gene polymorphism and IgA nephropathy: An ethnically homogeneous study and a meta-analysis // Kidney Int. -2001. Vol. 60. — P. 732−740.
- Shiavello T., Burke V., Bogdanova N. et al. Angiotensin-Converting enzyme activity and the ACE Alu polymorphism in autosomal dominant polycystic kidney disease // Nephrol. Dial. Transplant. 2001. — Vol. 16. — P. 2323−2327.
- Shunkert H., Riegger G. Association between a deletion polymorphism of the angiotensin converting enzyme gene and left ventricular hypertrophy // N. Engl. J. Med. 1994.-Vol. 330.-P. 1634−1638.
- Skidgel R.A., Erdos E.G. (1987) Clin. Exp. Hypert. A., 9, 243−259.
- Sugimura K., Tian X-L. Hoffmann S., Ganten D., Bader M. (1998) Biochem. Biophys. Res. Commun., 247, 466−472.
- Soubrier F., Alhenc-Gelas F., Hubert C., Allegrini J., John M., Tregear G., Corvol P. (1988) Proc. Natl. Acad. Sei. USA, 85, 9386−9390.
- Stein J, Me Bride P. Hyperhomocysteinemia and atherosclerotic vascular disease. Arch Intern Med 1998- 158: 1301−6.
- Sirrs S, Duncan L, Djurdjev O et al. Homocysteine and vascular access complications in hemodialysis patients: insights into a complex metabolic relationships. Nephrol Dial Transplant 1999- 14 (3): 738−743
- Stein G, Muller A, Busch M et al. Homocysteine, its metabolites, and B-group vitamins in renal transplant patients. Kidney Int 2001- 59 Suppl 78.: 262−265
- Sprouse, JT, Wong CS, Chandler WL, Williams GD, Watkins SL, and Tarr PI. Thrombogenic alleles, Escherichia coli 0157: H7 infections, and hemolytic uremic syndrome. Blood Coagul Fibrinolysis 12: 283−288, 2001
- Suzuki S., Suzuki Y., Kobayashi Y. et al. Insertion/deletion polymorphism in ACE gene is not associated with renal progression in Japanese patients with IgA nephropathy // Am. J. Kidney Dis. 2000. — Vol. 35. — P. 896−903.
- Stratta P., Canavese C., Ciccone G. et al. Angiotensin I-converting enzyme genotype significantly affects progression of IgA glomerulonephritis in an Italian population // Am. J. Kidney Dis. 1999. — Vol. 33. — P. 1071−1079.
- Syrjanen J., Huang X.H., Mustonen J. et al. Angiotensin-converting enzyme insertion/deletion polymorphism and prognosis of IgA nephropathy // Nephron. — 2000. — Vol. 86.-P. 115−121.
- Stefansson, S, and Lawrence DA. The serpin PAI1 inhibits cell migration by blocking integrin alpha V beta 3 binding to vitronectin. Nature 383: 441−443, 1996
- Sun Y., Ratajska A., Zhou G.P., Weber K.T. (1993) J. Lab. Clin. Med., 122, 395 403.
- Tiret L., Blanc H., Ruidavets J.B., Arveiler D. et al. (1998) J. Hypert., 16, 37−44.
- Tanaka R., Iijima K., Murakami R. et al. ACE gene polymorphism in childhood IgA nephropathy: association with clinicopathologic findings // Am. J. Kidney Dis. 1998. -Vol. 31.-P. 774−779
- Tomooka, S, Border WA, Marshall BC, and Noble NA. Glomerular matrix accumulation is linked to inhibition of the plasmin protease system. Kidney Int 14 621 469, 1992
- Tamaki, K, Okuda S, Nakayama M, Yanagida T, and Fujishima M. Transforming growth factor-beta 1 in hypertensive renal injury in Dahl salt-sensitive rats. J Am Soc Nephrol 7: 2578−2589, 1996
- Tawakol A, Omland T, Gerhard M et al. Hyperhomocyst (e)inemia is associated with impaired endothelium-dependant vasodilatation in humans. Curculation 1997- 95: 111 9— 21.
- Troyer, DA, Chandrasekar B, Thinnes T, Stone A, Loskutoff DJ, and Fernandes G. Effects of energy intake on type 1 plasminogen activator inhibitor levels in glomeruli of lupus-prone B/W mice. Am J Pathol 146: 111−120, 1995
- Tiret L., Blanc H., Ruidavets J.B., Arveiler D. et al. (1998) J. Hypert., 16, 37−44.
- Tsukahara H, Hiraoca M, Nishida K, Kobata R, Tsuchida S, Toyooka M, Kimura H, Gejyo F, Mayumi M Methylenetetrahydrofolate reductase polymorphism in Kawasaki disease Pediatr Int.2000 Jun- 42(3): 236−40.
- Tomooka, S, Border WA, Marshall BC, and Noble NA. Glomerular matrix accumulation is linked to inhibition of the plasmin protease system. Kidney Int 42: 14 621 469, 1992
- Tiret L., Bonnardeaux A., Poirier O. et al. Synergistic effects of angiotensin -converting enzyme and angiotensin-II type I receptor gene polymorphisms on risk of myocardial infarction // Lancet. 1994. — Vol. 334. — P. 910−913.
- Yamamoto, T, Noble NA, Cohen AH, Nast CC, Hishida A, Gold LI, and Border WA. Expression of transforming growth factor-P isoforms in human glomerular diseases. Kidney Int 49: 461−469, 1996
- Yamamoto, T, Nakamura T, Noble NA, Ruoslahti E, and Border WA. Expression of transforming growth factor P is elevated in human and experimental diabetic nephropathy. Proc Natl Acad Sci USA 90: 1814−1818, 1993
- Yoshida H., Kuriyama S., Atsumi Y. et al. Angiotensin I converting enzyme gene polymorphism in non-insulin dependent diabetes mellitus // Kidney Int. 1996. — Vol. 50.-P. 657−664.
- Wang, AY, Poon P, Lai FM, Yu L, Choi PC, Lui SF, and Li PK. Plasminogen activator inhibitor-1 gene polymorphism 4G/4G genotype and lupus nephritis in Chinese patients. Kidney Int 59: 1520−1528, 2001
- Wilke A., Funck R., Rupp H., Brilla C.G. (1996) Basic Res. Cardiology, 91, Suppl. 2, 79−84.
- Wang AY, Poon P, Lai FM, Yu L, Choi PC, Lui SF, Li PK. Plasminogen activator inhibitor-1 gene polymorphism 4G/4G genotype and lipus nephritis in Chinese patients. Kidney Int. 2001 Apr: (4): 1520−8 China
- Wolf G., Neilson E.G. Angiotensin II as a renal growth factor. I Am Soc Nephrol 1993−3:1531−1540.
- Welch G, Loscalo J. Homocysteine and atherosclerosis. New Engl J Med 1998- 338 (15): 1042−50.
- Warren C. Emergent cardiovascular risk factor: Homocysteine. Prog Cardiovasc Nurs 2002- 17: 351.
- Welch G, Upchurch G, Loscalo J. Hyperhomoceyst (e)inemia and atherothrombosis. Ann NY Acad Sei 1997- 811:48−58.
- Wrone EM, Zehnder JL, Hornberger JM et al. An MTHFR variant, homocysteine and cardiovascular comorbidity in renal disease. Kidney Int 2001- 60 (3): 1106−1114
- Wanner C, Zimmermann J, Swedler S, Metzger T. Inflammation and cardiovascular risk in dialysis patients. Kidney Int 2002−61(1):99
- Wolf, G, Mueller E, Stahl RAK, and Ziyadeh FN. Angiotensin II induced hypertrophy of cultured murine proximal tubular cells is mediated by endogenous transforming growth factor-?. J Clin Invest 92: 1366−1372, 1993
- Vasku A., Soucek M., Znojil V. et al. Angiotensin I-converting enzyme and angiotensinogen gene interaction and prediction of essential hypertension // Kidney Int. -1998. Vol. 53. — P. 1479−1482
- Xu, Y, Hagege J, Mougenot B, Sraer JD, Ronne E, and Rondeau E. Different expression of the plasminogen activation system in renal thrombotic microangiopathy and the normal human kidney. Kidney Int 50: 2011−2019, 1996
- Yorioka T., Suehiro T., Yasuoka N. et al. Polymorphism of the angiotensin converting enzyme gene and clinical aspects of IgA nephropathy // Clin. Nephrol. -1995.-Vol. 44.-P. 80−85.
- Yoshida H., Kuriyama S., Atsumi Y. et al. Angiotensin I converting enzyme gene polymorphism in non-insulin dependent diabetes mellitus // Kidney Int. 1996. — Vol. 50.-P. 657−664.
- Yamamoto, K, and Loskutoff DJ. The kidneys of mice with autoimmune disease acquire a hypofibrinolytic/procoagulant state that correlates with the development of glomerulonephritis and tissue microthrombosis. Am J Pathol 151: 725−734, 1997
- Zou C, Tsukahara H, Hiraoka M, Mizu J, TodorokaY, Ohshima Y, Kimura H, Tsuzuki K, Mayumi M. Methylenetetrahydrofolate reductase polymorphism in childhood primary focal segmental glomerulosclerosis Nephron 2002 Oct- 92(2): 449−51.
- Zhonghua Ney Ke Za Zhi. YaoY, Liu H, Zhang X Duan X. China 2002 / Methylenetetrahydrofolate reductase gene polymorphism and plasma homocysteine levels in hemodialysing patients Aug: 41(8): 522−5
- Zee R.Y.L., Lou Y., Griffiths L.R., Morris B.J. Association of a polymorphism of the angiotensin I converting enzyme gene with essential hypertension // Biochem. Biophys. Res. Commun. 1992. — Vol. 184. — P. 9−15